Avalo Therapeutics (AVTX) Amortizatization of Intangibles (2017 - 2026)
Avalo Therapeutics posted quarterly Amortizatization of Intangibles of $106000.0 for Q1 2026, down 46.19% on a QoQ basis from $197000.0 in Q4 2025.
Avalo Therapeutics (AVTX) has 8 years of Amortizatization of Intangibles data on file, last reported at $106000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles changed N/A year-over-year to $106000.0; the trailing twelve-month figure through Mar 2026 stood at $796000.0 (changed N/A YoY), and the FY2025 full-year result was $690000.0, changed N/A from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $106000.0, down from $197000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $900000.0 in Q3 2023 and bottomed at $106000.0 in Q1 2026.
- The 4-year median for Amortizatization of Intangibles is $349000.0 (2022), against an average of $344000.0.
- Peak annual rise in Amortizatization of Intangibles reached 223.08% in 2022, while the deepest fall reached 0.0% in 2022.
- A 4-year view of Amortizatization of Intangibles shows it stood at $349000.0 in 2022, then jumped by 157.88% to $900000.0 in 2023, then slumped by 78.11% to $197000.0 in 2025, then sank by 46.19% to $106000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $106000.0 (Q1 2026), $197000.0 (Q4 2025), and $347000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 106,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 106,000.00 |
| Mar 31, 2026 | 106,000.00 |
| Dec 31, 2025 | 197,000.00 |
| Dec 31, 2025 | 197,000.00 |
| Sep 30, 2025 | 347,000.00 |
| Sep 30, 2025 | 347,000.00 |
| Jun 30, 2025 | 146,000.00 |
| Jun 30, 2025 | 146,000.00 |
| Sep 30, 2023 | 900,000.00 |
| Sep 30, 2023 | 900,000.00 |
| Jun 30, 2023 | 349,000.00 |
| Jun 30, 2023 | 349,000.00 |
| Mar 31, 2023 | 350,000.00 |
| Mar 31, 2023 | 350,000.00 |
| Dec 31, 2022 | 349,000.00 |
| Dec 31, 2022 | 349,000.00 |
| Sep 30, 2022 | 354,000.00 |
| Sep 30, 2022 | 354,000.00 |
| Jun 30, 2022 | 336,000.00 |
| Jun 30, 2022 | 336,000.00 |
| Mar 31, 2022 | 350,000.00 |
| Mar 31, 2022 | 350,000.00 |
| Dec 31, 2021 | 349,000.00 |
| Dec 31, 2021 | 349,000.00 |
| Sep 30, 2021 | 341,000.00 |
| Sep 30, 2021 | 341,000.00 |
| Jun 30, 2021 | 104,000.00 |
| Jun 30, 2021 | 104,000.00 |
| Dec 31, 2019 | -1.00 |
| Dec 31, 2019 | -1.00 |
| Sep 30, 2019 | 67,032.00 |
| Sep 30, 2019 | 67,032.00 |
| Jun 30, 2019 | 17,637.00 |
| Jun 30, 2019 | 17,637.00 |
| Mar 31, 2019 | 22,603.00 |
| Mar 31, 2019 | 22,603.00 |
| Dec 31, 2018 | 38,154.00 |
| Dec 31, 2018 | 38,154.00 |
| Sep 30, 2018 | 85,181.00 |
| Sep 30, 2018 | 85,181.00 |
| Jun 30, 2018 | 131,788.00 |
| Jun 30, 2018 | 131,788.00 |
| Mar 31, 2018 | 45,450.00 |
| Mar 31, 2018 | 45,450.00 |
| Dec 31, 2017 | 137,900.00 |
| Dec 31, 2017 | 137,900.00 |